Optimizing tumor study performance: Evaluating the B-NDG & NSG™ models in PDX and CDX tumor studies.

It's estimated than less than 10% of investigational anti-cancer drugs successfully achieve FDA approval for clinical use. This is often attributed to the fact that it’s difficult to identify patients whose tumors are most likely to respond to a specific treatment. Patient derived xenografts (PDXs) are bringing new hope when it comes to this challenging task, yet finding the ideal animal model to grow the PDX tumors to test new therapies can be challenging. The new B-NDG mouse model is our newest triple immunodeficient mouse with proven performance in cancer and immuno-oncology research. Join this webinar to learn more about the model and how the B-NDG compares to existing models like the JAX^® NSG™ mice in CDX and PDX tumor studies.

 

Learning Objectives